Astellas Pharma has unveiled CSP2026, a five-year corporate strategic plan for fiscal years 2026–2030 designed to accelerate pipeline-led growth, strengthen its financial position and support sustainable shareholder returns. The company said it is aiming to achieve record-high, pipeline-driven revenues by the mid-2030s while delivering “greater VALUE faster” for patients through its Strategic Brands and late-stage R&D portfolio.
Under CSP2026, Astellas has outlined several key deliverables, including initiating more than 10 Phase 3 or pivotal studies by fiscal 2030, with at least five of those studies starting by fiscal 2027. The company is targeting cumulative core operating profit before R&D expenses of more than 4.3 trillion yen over the plan period and aims to double revenue from its high-margin Strategic Brands versus fiscal 2025. It also plans recurring cost optimization of 200 billion yen and a 50% ratio of core operating profit before R&D to revenue, while committing to a minimum annual dividend increase of 2 yen.
To reach these goals, Astellas has set four strategic objectives focused on growth, the pipeline, capital allocation and productivity. On the commercial side, the company said it will maximize revenue from its Strategic Brands—PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA—by pursuing new indications, especially for PADCEV and VYLOY, and expanding launches in growth markets. Astellas expects sales of these brands to double by fiscal 2030 compared with fiscal 2025, providing a steady source of cash to fund R&D and future launches.
On the R&D front, Astellas plans to accelerate pipeline-led growth from fiscal 2029, boosted by earlier programs from its Focus Area approach that have already achieved proof of concept and entered Phase 3. During CSP2026, the company intends to start more than 10 Phase 3 or pivotal trials, five or more of them by fiscal 2027, while continuing targeted business development to strengthen late-stage assets. Astellas said it aims to unlock pipeline revenue potential of about 1 trillion yen in the mid-2030s.
The plan also emphasizes disciplined capital allocation and cost control. Astellas expects to reach a 30% core operating margin by fiscal 2027 and to generate more than 4.3 trillion yen in core operating profit before R&D over the CSP2026 period, creating an internal funding base for growth. The company intends to maintain core operating profit before R&D at 50% of revenue, giving flexibility to increase R&D investment as programs advance, and will pursue 200 billion yen in cumulative cost optimization to support profitability, growth investment and shareholder returns, including an annual dividend increase of at least 2 yen.
CSP2026 includes measures to enhance enterprise productivity by building on Astellas’ cultural foundation, governance and ways of working. The company said it has reorganized around a “patient axis” to speed decision-making and outcomes across the value chain and is evolving its operating model by delegating greater authority to cross-functional Asset Maximization Teams. President and CEO Naoki Okamura said Astellas is “well positioned” for strong performance through 2030 and beyond, and that with these changes and its Values and Behaviors as a guide, the company intends to deliver sustainable growth while advancing its vision of being at the forefront of healthcare change.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!